3.0
21. Jan. 2012
Aktueller Mitarbeiter
Philadelphia, PA
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Great to be creating something that cures diseases Benefits are good (middle of road for pharma) Great when compared to other industries
Kontras
Constant churn due to merger and reorganizations. Unable to create new products that can replace those facing the patent cliff makes it a company that has a lot of stress.